Their product Exparel will continue to gain market share as inpatient surgeries transition to outpatient. This product is gaining traction in the joint replacement procedures. It is a game changer for physicians, patients and surgery centers.

Produces one drug that is in early adopter phase and starting into more common use. This sky is the limit as more users and uses come on board. Fatal flaw could be if clinical finding of a problem with their one drug occurs; company could die quickly. I would expect this company to be purchased in next two years by a larger pharmaceutical company.